Taiho Oncology Publishes P-II Trial (FOENIX*-CCA2) Results of Futibatinib for Metastatic Intrahepatic Cholangiocarcinoma in NEJM
Shots:
- The P-II trial (FOENIX*-CCA2) evaluating futibatinib in 103 patients with previously treated, unresectable, LA or metastatic iCCA harboring FGFR2 gene fusions or other rearrangements
- The result showed ORR (42%) & had a DoR of 9.7mos., DCR (83%). At the data cutoff in Oct 2020 for the primary analysis, the median follow-up was 17.1mos. & median treatment duration was 9.1mos., ORR was observed across all protocol-specified subgroups, m-PFS (9.0mos.) & m-OS (21.7mos.) while similar response & survival data were reported at follow-up 8.0mos.
- The study also reported stable QoL over 9mos. while PROs were evaluated as a prespecified secondary objective, no meaningful changes from baseline across the observed study period in EORTC-QLQ-c30 QoL scales were seen
Ref: PRNewswire | Image: Taiho
Related News:- Taiho’s Lytgobi (futibatinib) Receives the US FDA’s Approval for the Treatment of Intrahepatic Cholangiocarcinoma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
